Fig. 2From: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialCumulative incidence of responses in the chronic phase (A) and accelerated phase (B) MCyR, major cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response; MR4.0, molecular response 4; MR4.5, molecular response 4.5.Back to article page